The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Biotest Aktiengesellschaft (BIO3:F) Annual Income Statement ()
BIO3:F Quarterly Financials ()
Frequently Asked Questions About Biotest Aktiengesellschaft (BIO3:F) Stock
Biotest Aktiengesellschaft's (BIO3:F) last reported annual revenue was EUR 684.60 Million.
Biotest Aktiengesellschaft's (BIO3:F) annual revenue growth rate based on the revenue reported in the past 5 years is : 11.33%
Biotest Aktiengesellschaft's(BIO3:F) is profitable as of its last reported annual financials.
The net profit margin for Biotest Aktiengesellschaft's(BIO3:F) from its laster reported year is 18.55%
The return on equity (ROE) for Biotest Aktiengesellschaft's(BIO3:F) from its last reported annual financials is : 36.16%
The return on assets (ROA) for Biotest Aktiengesellschaft's(BIO3:F) from its last reported annual financials is : 8.47%
The return on invested capital (ROIC) for Biotest Aktiengesellschaft's(BIO3:F) from its last reported annual financials is : 12.18%
The Debt to Equity ratio for Biotest Aktiengesellschaft's(BIO3:F) from its last reported annual financials is : 66.05%
The dividend yield for Biotest Aktiengesellschaft's(BIO3:F) from its laster reported year is 0.15%
Biotest Aktiengesellschaft's(BIO3:F) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIO3:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
